

July 31th, 2002

Kyorin Pharmaceutical Co., Ltd.
5 Kanda, Surugadai 2 - chome, Chiyoda-ku, Tokyo

KYORIN COMMENCES A NEW JOINT RESEARCH PROJECT WITH SCOTTISH BIOMEDICAL

Kyorin Pharmaceutical Co., Ltd. (President: Ikuo Ogihara) is pleased to announce that Kyorin has entered into, as of the 16th day of July 2002, development agreement with the Scottish Biomedical Foundation Limited (Scottish Biomedical) to identify and optimize novel drug candidates in the area of metabolic diseases (for type-2 diabetes) at Kyorin Scotland Research Laboratory.

Kyorin currently focuses its scope of R&D segments on three fields, such as infectious diseases, immunology & allergy and metabolic diseases under its franchise management strategy. Kyorin is developing a new drug discovery networks with leading discovery research institutes in US, EU and Japan and is taking a policy to explore drug seeds more efficiently. Kyorin Scotland Research Laboratory was established in conjunction with Scottish Biomedical in November 2000 in which we can conduct the discovery research, being linked with the technology from the six principle Universities in Scotland.

In Kyorin Scotland Research Laboratory we have carried out the drug discovery research in the field of immunology & allergy. In addition to it we signed the three-year collaboration with Scottish Biomedical in the metabolic disease area to strengthen our capability of drug discovery in this area. We will invest approximately one billion yen in total during the collaboration period. The project team comprises thirteen researchers and five consultants.

Profile of Kyorin Scotland Research Laboratory

Establishment : November 2000
Location : Todd Campus, West of Scotland Science Park, Glasgow, G20 OXA,
Scotland
Research Staff : 26 researchers and 10 consultants
Research Fields : Immunology & Allergy and Metabolic Diseases